Private Capital Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Private Capital Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-69	Closed	-$2K	–	2143
2021 Q2	$2K	Buy	+69	New	+$1.56K	﹤0.01%	1799
2020 Q3	–	Sell	-27	Closed	-$1K	–	1993
2020 Q2	$1K	Hold	27	–	–	﹤0.01%	1787
2020 Q1	$1K	Hold	27	–	–	﹤0.01%	1753
2019 Q4	$1K	Buy	+27	New	+$1.18K	﹤0.01%	1766

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Private Capital Group's ACAD Position: Q3 2021 in Review

Private Capital Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 69 shares — an estimated $2K sold.

Private Capital Group first reported a position in ACAD in Q4 2019 and held it in 4 quarters. The position peaked at $2K in Q2 2021. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

Private Capital Group reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Private Capital Group sold 69 Acadia Pharmaceuticals shares in Q3 2021, an estimated $2K.
Private Capital Group first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 4 quarters.
Private Capital Group's Acadia Pharmaceuticals position peaked at $2K in Q2 2021.
237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Private Capital Group's 13F filing for Q3 2021, filed 13 Oct 2021.